Home Cart Sign in  
Chemical Structure| 927880-90-8 Chemical Structure| 927880-90-8

Structure of RAF265
CAS No.: 927880-90-8

Chemical Structure| 927880-90-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RAF265 is a pan-inhibitor that inhibits C-Raf, B-Raf and B-Raf V600E with IC50 of 3 nM-60 nM. It also shows inhibition on phosphorylation of VEGFR2 with EC50 of 30 nM.

Synonyms: CHIR-265

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RAF265

CAS No. :927880-90-8
Formula : C24H16F6N6O
M.W : 518.41
SMILES Code : FC(C1=CC=C(NC2=NC3=CC(OC4=CC(C5=NC=C(C(F)(F)F)N5)=NC=C4)=CC=C3N2C)C=C1)(F)F
Synonyms :
CHIR-265
MDL No. :MFCD16659061
InChI Key :YABJJWZLRMPFSI-UHFFFAOYSA-N
Pubchem ID :11656518

Safety of RAF265

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of RAF265

RTK
MAPK

Isoform Comparison

Biological Activity

Target
  • VEGFR2

    VEGFR2, EC50:30 nM

  • B-Raf

    B-Raf, IC50:3 nM-60 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MV4;11 cells 1.0 μM 24 hours To evaluate the inhibitory effect of RAF265 on FDG accumulation in MV4;11 cells, results showed that RAF265 did not significantly inhibit FDG accumulation at 24 hours. PMC3050869
MV4;11 cells 0.1 μM 24 hours To evaluate the inhibitory effect of RAF265 on FDG accumulation in MV4;11 cells, results showed that RAF265 did not significantly inhibit FDG accumulation at 24 hours. PMC3050869
A375M cells 1.0 μM 28 hours To evaluate the inhibitory effect of RAF265 on FDG accumulation in A375M cells, results showed that RAF265 significantly inhibited FDG accumulation at 28 hours with an inhibition rate of 75.5%. PMC3050869
A375M cells 0.1 μM 28 hours To evaluate the inhibitory effect of RAF265 on FDG accumulation in A375M cells, results showed that RAF265 significantly inhibited FDG accumulation at 28 hours with an inhibition rate of 38.2%. PMC3050869
A549 0.1 to 2.5 μM 4 h RAF265 induced paradoxical ERK activation at low/intermediate concentrations (0.1 to 2.5 μM), with relatively little changes occurring at the level of MEK and p90RSK phosphorylation PMC6038340
MiaPaCa2 0.1 to 2.5 μM 4 h RAF265 induced paradoxical ERK activation at low/intermediate concentrations (0.1 to 2.5 μM), with relatively little changes occurring at the level of MEK and p90RSK phosphorylation PMC6038340
B-CPAP 200 nM 5 days RAF265 significantly inhibited the proliferation of B-CPAP cells and showed synergistic effects when combined with BEZ-235. PMC4828042
TT 200 nM 5 days RAF265 significantly inhibited the proliferation of TT cells and showed synergistic effects when combined with BEZ-235. PMC4828042
CAL62 200 nM 5 days RAF265 significantly inhibited the proliferation of CAL62 cells and showed synergistic effects when combined with BEZ-235. PMC4828042

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Human metastatic melanoma tumor model Oral 40 mg/kg Once daily for 30 days To evaluate the effect of RAF265 on the growth of human metastatic melanoma tumors, results showed that 7/17 tumors responded to RAF265 treatment with more than 50% reduction in tumor volume PMC3724517
Nude mice CAL62 and TT xenograft models Oral 10 mg/kg thrice weekly, throughout the experiment RAF265 significantly inhibited tumor growth in CAL62 and TT xenograft models and showed enhanced inhibition when combined with BEZ-235. PMC4828042
Nude mice A375M tumor xenograft model Oral 100 mg/kg every 3 days for 15 days To evaluate the inhibitory effect of RAF265 on FDG accumulation in the A375M tumor xenograft model, results showed that RAF265 significantly inhibited FDG accumulation as early as 1 day after treatment, and the inhibitory effect persisted until the end of treatment. PMC3050869

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00304525 Metastatic Melanoma PHASE1|PHASE2 COMPLETED 2025-11-13 University of Colorado Univ.of... More >>ColoradoCancerCenter, Aurora, Colorado, 80045, United States|Georgia Regents University Cancer Clinical Research Unit, Augusta, Georgia, 30912, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology, Baltimore, Maryland, 21231, United States|Massachusetts General Hospital Dept of Cancer for Melanoma, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute DFCI, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center Dept.ofBethIsraelDeaconess(3), Boston, Massachusetts, 02215, United States|University of Pennsylvania Health System Dept of Hospital of UnivofPenn, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh Cancer Institute Dept of Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt University Medical Center Dept. of Cancer Center, Nashville, Tennessee, 37232, United States|University of Texas/MD Anderson Cancer Center Onc. Dept,, Houston, Texas, 77030-4009, United States|Novartis Investigative Site, Zürich, 8091, Switzerland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.64mL

1.93mL

0.96mL

19.29mL

3.86mL

1.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Mordant P, Loriot Y, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9(2):358-68.

[2]Zitzmann K, de Toni E, et al. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85.

[3]Williams TE, Subramanian S, et al. Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett. 2015 Aug 3;6(9):961-5.

[4]Chow AK, Cheng NS, et al. Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma. Mol Cancer. 2015 Apr 11;14:80.

[5]Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. doi: 10.1186/1756-8722-6-30. PMID: 23617957; PMCID: PMC3646677.

[6]Williams TE, Subramanian S, Verhagen J, McBride CM, Costales A, Sung L, Antonios-McCrea W, McKenna M, Louie AK, Ramurthy S, Levine B, Shafer CM, Machajewski T, Renhowe PA, Appleton BA, Amiri P, Chou J, Stuart D, Aardalen K, Poon D. Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett. 2015 Aug 3;6(9):961-5. doi: 10.1021/ml500526p. PMID: 26396681; PMCID: PMC4569875.

[7]Mordant P, Loriot Y, Leteur C, Calderaro J, Bourhis J, Wislez M, Soria JC, Deutsch E. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther. 2010 Feb;9(2):358-68. doi: 10.1158/1535-7163.MCT-09-1014. Epub 2010 Feb 2. PMID: 20124452.

 

Historical Records

Categories